Data / Drug companies / Innovus Pharmaceuticals, Inc.
Innovus Pharmaceuticals, Inc.: 23 products in the FDA NDC directory, labeler code 57483
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Innovus Pharmaceuticals, Inc. (labeler code 57483) lists 23 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 23 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 27, 2026.
The request: Watch Innovus Pharmaceuticals, Inc. (FDA labeler code 57483): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 57483
- Products in commercial distribution
- 23
- Packages
- 27
- Finished drugs by generic name
- 14
- Prescription products
- 0
- Over the counter products
- 23
- Flagged as original packager
- 21 of 21 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- March 25, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 95.7% |
| Over the counter monograph drugs | 1 | 4.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 23 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Minoxidil | 4 | 113 |
| Omeprazole | 3 | 106 |
| Esomeprazole magnesium | 2 | 77 |
| Loratadine | 2 | 125 |
| Cetirizine hydrochloride | 2 | 119 |
| Fexofenadine hydrochloride | 2 | 65 |
| Hemorrhoidal suppositories | 1 | 2 |
| Fluticasone propionate | 1 | 71 |
| Guaifensin extended-release | 1 | 1 |
| Guaifenesin | 1 | 123 |
| Guaifenesin extended-release | 1 | 1 |
| Diclofenac sodium | 1 | 109 |
| Diclofenac sodium topical gel 1% | 1 | 1 |
| Guaifenesin and dextromethorphan hbr | 1 | 26 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 6 | 26.1% |
| Aerosol, foam | 4 | 17.4% |
| Capsule, delayed release | 3 | 13% |
| Tablet, orally disintegrating | 2 | 8.7% |
| Tablet, delayed release | 2 | 8.7% |
| Tablet, extended release | 2 | 8.7% |
| Gel | 2 | 8.7% |
| Suppository | 1 | 4.3% |
| Spray, metered | 1 | 4.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Guaifenesin | 57483-144 | Tablet, extended release | Generic drugs (ANDA) | October 27, 2026 |
| Guaifenesin and Dextromethorphan HBr | 57483-114 | Tablet, extended release | Generic drugs (ANDA) | October 27, 2026 |
| Regoxidine (for women) | 57483-175 | Aerosol, foam | Generic drugs (ANDA) | May 3, 2025 |
| Regoxidine (for men) | 57483-165 | Aerosol, foam | Generic drugs (ANDA) | May 3, 2025 |
| Cetirizine Hydrochloride (Allergy) | 57483-190 | Tablet | Generic drugs (ANDA) | April 28, 2025 |
| Diclofenac sodium | 57483-185 | Gel | Generic drugs (ANDA) | March 25, 2025 |
| Fluticare | 57483-180 | Spray, metered | Generic drugs (ANDA) | February 28, 2025 |
| Esomeprazole Magnesium | 57483-225 | Capsule, delayed release | Generic drugs (ANDA) | May 25, 2023 |
| Acid Reducer | 57483-120 | Tablet, delayed release | Generic drugs (ANDA) | May 25, 2023 |
| Allervarx | 57483-955 | Tablet, orally disintegrating | Generic drugs (ANDA) | June 4, 2022 |
| Allervarx | 57483-950 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 30, 2022 |
| Crcle Diclofenac Sodium Topical Gel 1% | 57483-596 | Gel | Generic drugs (ANDA) | January 10, 2022 |
| Crcle Cetirizine Hydrochloride | 57483-250 | Tablet | Generic drugs (ANDA) | June 30, 2021 |
| Crcle Fexofenadine Hydrochloride | 57483-240 | Tablet | Generic drugs (ANDA) | December 18, 2020 |
| Crcle Fexofenadine Hydrochloride | 57483-230 | Tablet | Generic drugs (ANDA) | December 18, 2020 |
| Crcle Guaifensin Extended Release Tablet, 1200 mg | 57483-280 | Tablet | Generic drugs (ANDA) | September 10, 2020 |
| Crcle Guaifenesin Extended-Release Tablets, 600 mg | 57483-270 | Tablet | Generic drugs (ANDA) | September 10, 2020 |
| Esomeprazole | 57483-900 | Capsule, delayed release | Generic drugs (ANDA) | August 14, 2020 |
| Omeprazole | 57483-840 | Tablet, delayed release | Generic drugs (ANDA) | August 10, 2020 |
| Omeprazole | 57483-740 | Capsule, delayed release | Generic drugs (ANDA) | August 6, 2020 |
| Regoxidine (For Women) | 57483-540 | Aerosol, foam | Generic drugs (ANDA) | April 22, 2019 |
| Regoxidine (For Men) | 57483-530 | Aerosol, foam | Generic drugs (ANDA) | January 2, 2019 |
| Xyralid Hemorrhoidal | 57483-410 | Suppository | Over the counter monograph drugs | March 25, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.